IRCT2017060228381N1CompletedPhase 2
Antibiotic therapy for premature rupture of membranes and maternal outcomes in sayyad shirazi hospital-Gorgan
*Golestan University of Medical Sciences0 sites140 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 140
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 41 years (—)
- Sex
- Female
Inclusion Criteria
- •Conditions of entry:
- •Pregnant women with complaints of irritation between 34-24 weeks of pregnancy after ensuring rupture of membranes-by examination and testing Nitrazine;
- •Exclusion criteria:Positive rectovaginal culture.
- •Sample size: 140; divided into two groups of 70 pregnant woman.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Not yet recruiting
Phase 3
A randomized controlled trial on the effectiveness of prophylactic antibiotics compared to standard therapy on prevention of feto maternal and neonatal infections.Prelabour rupture of membrane(PROM)SLCTR/2019/033Professorial unit- Obstetics & Gynaecology
Completed
Not Applicable
PPROM Erythromycin Versus AzithromycinPreterm Premature Rupture of MembranesNCT01431248University of Oklahoma7
Withdrawn
Phase 3
Erythromycin Versus Azithromycin in Preterm Premature Rupture of MembranesPreterm Premature Ruptured MembranesNCT01556334Indiana University
Active, not recruiting
Phase 1
HEMODIALYSIS AND ANTIBIOTIC PROPHYLAXISSevere infection in patients end stage kidney disease and in hemodialysis with CVC as vascular asscess.MedDRA version: 20.0Level: LLTClassification code 10023420Term: Kidney failure chronicSystem Organ Class: 100000004857EUCTR2020-001033-12-DKiels Eske Bruun800
Completed
Not Applicable
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy-C900 Multiple myelomaC900Multiple myelomaPER-011-06EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),